€2.67
+0.05 (+1.91%)
EUR · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BIOBV.HE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine PatientsNCT02315833Number of migraine attacks (NMA) per evaluation intervalRandomized · Quadruple-masked · Treatment | Not applicable | Completed | Drug: Acetium, Placebo | Migraine | 200 | 2019-07-02actual | 2021-02-17 |
| The Efficacy of L-cysteine in Prevention of Cluster HeadacheNCT02310828The frequency of headache attacks per weekRandomized · Quadruple-masked · Treatment | Not applicable | Completed | Drug: Acetium, Placebo | Cluster Headache | 60 | 2019-02-08actual | 2021-02-17 |
| The Efficacy of Acetium Lozenges in Intervention for Smoking CessationNCT02758743Prolonged abstinence (PA), based on smoking diaryRandomized · Quadruple-masked · Other | Not applicable | Completed | Drug: Acetium Lozenge, Placebo | Smoking Cessation | 1,998 | May 2017actual | 2017-06-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19